Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators... see more

TSX:QIPT - Post Discussion

Quipt Home Medical Corp > QIPT Financial Forecast - Annual -2024/2028
View:
Post by sollmg on Jun 18, 2024 10:02am

QIPT Financial Forecast - Annual -2024/2028

Financial Forecast

Revenue This Year
267.54M
Increased by20.65%
Revenue Next Year
289.05M
Increased by8.04%
EPS This Year
-0.03
EPS Next Year
0.11
Year 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Revenue
80.97M 72.64M 102.35M 139.86M 221.74M 267.54M 289.05M 340.95M 505.28M 581.09M
Revenue Growth
- -10.29% 40.90% 36.65% 58.54% 20.65% 8.04% 17.96% 48.20% 15.00%
EPS
-0.36 -0.20 -0.20 0.13 -0.07 -0.03 0.11 0.38 1.24 1.60
EPS Growth
- - - - - - - 252.20% 225.18% 28.86%
Forward PE
- - - - - - 30.43 8.64 2.66 2.06
No. Analysts - - - - - 9 7 5 3 3
Comment by mjh9413 on Jun 18, 2024 1:28pm
Not long but keep watching this one out of intrigue more than anything else. Find the analyst ratings 'unreliable.' from $3.53 to about $10 done in May by 6 analysts (I find the first 4 letters generall speak a lot to what these people come up with, particularly when they are involved in financings, which all of them I believe were in that 04/23 bought deal at $7,75, Seems like they ...more  
Comment by westcoastlogger on Jun 18, 2024 2:36pm
Its a growth stock with a current DOJ investigation hanging over its head because someone forgot to dot an i or cross a t on a purchase agreement. When that will be over is anyones guess and we would be positive EPS if we weren't spending money on growing the company. Or we may be bought out next Tuesday for all anyone knows. Thats why I'm longer than a Norwegian ski here.
Comment by KarlGibbons on Jun 18, 2024 8:25pm
QIPT is not a growth company.  They had negative growth last Q sequentially.  They will be flattish at best going forward without buying growth via acquisitions. The DOJ investigation is not someone forgetting to "dot an i or cross a t"....its very serious.  They don't pick up these cases without serious belief of wrongdoing, usually initiated by a whistleblower.
Comment by gibbonsj on Jun 19, 2024 11:38am
Karl I read your posts because we may share common ancestry but there's a lot of people in my family who are full of it. You would probably get along well with them.
Comment by Moemoney42 on Jun 19, 2024 4:35pm
Exactly Karl.. not to mention, management stated they won't be cash flow positive for 2 years.. a growth company.. LMAO..!!  Is this the chart of a "growth company"..???
Comment by lscfa on Jun 20, 2024 12:51am
Stop lying. Co. is cash flow positive now and never said it would take 2 years. What you reference is eps which is distorted with a lot of accounting BS like amort of intangibles.    Michael Freeman  I think we could squeeze just one more in one big shift that we've noticed from ‘22 to ‘23 is the shift from sort of positive to negative EPS. And I wonder if you provide ...more  
Comment by lscfa on Jun 20, 2024 12:52am
Michael Freeman I think we could squeeze just one more in one big shift that we've noticed from ‘22 to ‘23 is the shift from sort of positive to negative EPS. And I wonder if you provide sort of a rough outlook for 2024 in respect to earnings? Hardik Mehta If you know, company year-over-year you'll see some of the few contributors for the positive cashflow, or not cashflow, my bad ...more  
Comment by lscfa on Jun 20, 2024 1:08am
Accounting net income is a lousy metric, distorted by all sorts of BS accounting conventions. Focus on cash flow.     eps $US March June Sept December 2024 ($0.03)        ...more  
Comment by Moemoney42 on Jun 20, 2024 12:40pm
"Co. is cash flow positive now and never said it would take 2 years. What you reference is eps which is distorted with a lot of accounting BS like amort of intangibles." Well I stand corrected and re-iterate that even EPS metrics prove my point.. now for the TSX to have a whopping 1400 shares traded in over 3 hrs today confirms my point.. its not a "growth" company by any ...more  
Comment by HatrikSeLaine on Jun 21, 2024 12:25pm
Agreed.  Why are we not seeing NCIB volume these past few weeks.  Time to can the next Comp package in Q1 2025.  Seriously, these idiots are doing nothing to earn their fat pay envelopes.
Comment by Tropicalsun on Jun 22, 2024 10:10am
Any company that has a current NCIB, is only required to report the number of shares purchased under the program on a quarterly bases.
Comment by HatrikSeLaine on Jun 23, 2024 12:30pm
We are aware of this fact, but the paultry daily volume we're seeing in the past few weeks means they are not currently active with the NCIB.  We should be seeing daily maximums allowed by the NCIB at these ridiculously low prices.  It speaks volumes as to how they're sitting on their hands at this particular time.   Do they feel the share price is yet too high to start ...more  
Comment by lscfa on Jun 20, 2024 1:00am
The flat growth last qtr was due to a 1 time decrease to reimbursement rates which will not repeat.  Co. guided 8% to 10% organic growth going forward.  
Comment by KarlGibbons on Jun 23, 2024 9:51pm
It wasn't flat, it was a decline.  It was due not only due to reimbursement changes but also patient losses to competitors as highlighted in the PR.
Comment by lscfa on Jun 23, 2024 10:30pm
Liar. Mgmt guided 8%-10% organic growth going forward. It's in the NR.  
Comment by KarlGibbons on Jun 24, 2024 8:25am
Mgmt got on the 1st quarter conference call (halfway thru Q2) and talked of 8-10% organic growth...then showed a DECLINE when reporting Q2.  They made no mention of the capitation customer loss on the Q1 call...and they disclosed on the Q2 call that the organic growth assumptions assumed a reversal of the rural 75/25 expiry...who does that?  every other player AHCO, VMD etc incorporated ...more  
Comment by gibbonsj on Jun 24, 2024 10:28am
Clearly you're hanging around for something. Too risky to short at this point so what is it?
Comment by KarlGibbons on Jun 24, 2024 7:43pm
Why is it a risky short?  its been going down for 3.5 years!  why would that change.  It's actually been a very risky long! and poor performing.  I see nothing here to get excited about.  DOJ & SEC investigations, product disruption, shaky mgmt and board, no investor interest etc...what do you see? Given the revaluation of the DME sleep businesses, I suspect major ...more  
Comment by lscfa on Jun 25, 2024 2:37am
Stop misleading people. Co. is entering diabetes segment and cross selling CGMs and supplies at no extra cost to SG&A. 
Comment by EdinColorado on Jun 20, 2024 2:52pm
Schwab has rated QIPT as an "A" for a long time, during which it has lost over 30% of its value. Healthstream also garners an "A" rating, but its value has risen.
Comment by EdinColorado on Jun 20, 2024 2:53pm
Schwab has rated QIPT as an @A@ for a long time, during which it has lost over 30% of its value. Healthstream also garners an @A@ rating, but its value has risen.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities